ライフサイエンスコーパス: natriuretic

1 ic acid, which has both vasoconstrictive and natriuretic actions.

2 in SHHF, which was associated with diuretic, natriuretic and hypotensive effects.

3 n of immunological, complement, coagulation, natriuretic and matrix remodeling pathways up to two dec

4 a primary renal proximal tubule cell AT(2)R natriuretic defect in SHR that may contribute to the dev

5 To test whether cGMP could bypass the natriuretic defect in SHR, we infused 8-bromo-cGMP.

6 lt intake; this associated with an increased natriuretic, diuretic, and kaliuretic response during th

7 Our aim was to assess the diuretic and natriuretic effect of empagliflozin in combination with

8 At 14 days, the natriuretic effect of empagliflozin persisted, resulting

9 natriuretic peptides - referred to as atrial natriuretic factor or atrial natriuretic peptide (ANP) a

10 ve activity (RSNA); increased levels of anti-natriuretic hormones, such as angiotensin II and aldoste

11 rrespondent renal water reabsorption, limits natriuretic osmotic diuresis, and results in concurrent

12 N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overcome for

13 dy), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ).

14 n (83.0 vs. 28.5 ng/L; P < 0.05), and B-type natriuretic peptide (7,424.5 vs. 3,209.5 pg/mL; P < 0.05

15 ed to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type natriureti

16 iuretic peptide A (NPPA) encoding the atrial natriuretic peptide (ANP) causes inflammation, fibroblas

17 Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are

18 Atrial natriuretic peptide (ANP) is a peptide hormone that in r

19 Although atrial natriuretic peptide (ANP) is not amidated, Pam expressio

20 in the receptor-binding region of the A-type natriuretic peptide (ANP), demonstrating that they affec

21 Although neither atrial nor brain natriuretic peptide (ANP, BNP) is amidated, the major me

22 sin II (ANG II; vasoconstrictive) and atrial natriuretic peptide (ANP; vasodilatory) antagonize the b

23 associated with HF more closely than B-type natriuretic peptide (AUC = 0.97 versus 0.84, p = 0.011).

24 e determined whether plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I are ass

25 (NP) family, which also includes the B-type natriuretic peptide (BNP) and the C-type natriuretic pep

26 With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it re

27 are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) concentrations rise with nepri

28 at risk" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by docume

29 class (HR 1.50; 95% CI 1.02-2.2), log brain natriuretic peptide (BNP) levels (HR 1.45; 95% CI 1.15-1

30 iac volume loading and increased serum brain natriuretic peptide (BNP) levels.

31 nnervated by pruritoceptors expressing brain natriuretic peptide (BNP) most of them contained mRNA fo

32 43 ms; P = 0.05), an elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-brain natriu

33 t to derive a new staging system using brain natriuretic peptide (BNP) that would correlate with the

34 Brain natriuretic peptide (BNP) treatment increases heart func

35 ith an established biomarker for CVD, B-type Natriuretic Peptide (BNP), and echocardiographic paramet

36 Circulating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) concentr

37 The utility of B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP)

38 atriuretic peptide (ANP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating an endo

39 C-type natriuretic peptide (CNP) is a fundamental endothelial s

40 ro-BNP (NT-proBNP), proBNP(1-108), or C-type natriuretic peptide (CNP) is not well understood.

41 ional risk factors and N-terminal pro-B-type natriuretic peptide (hazard ratio per SD increment: 1.35

42 ANP is a member of the natriuretic peptide (NP) family, which also includes the

43 Circulating natriuretic peptide (NP) levels are markedly lower in he

44 Phosphodiesterase-9 (PDE9) reduces natriuretic peptide (NP) signaling and may be involved i

45 alised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than

46 tion (LVEF) >=55%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >=300 pg/ml.

47 ent staging systems use N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T

48 awn for the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity car

49 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity car

50 Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone l

51 roponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infe

52 ce (6MWD) and change in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy.

53 g microRNA panels with N-terminal pro-B-type natriuretic peptide (NT-proBNP) clearly improved specifi

54 ortional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from basel

55 Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts p

56 wever, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHI

57 tril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations.

58 s biosensors to measure N-terminal pro-brain natriuretic peptide (NT-proBNP) in human serum within it

59 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a marker t

60 uretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP) level, an elevated E/A r

61 tone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usu

62 walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health statu

63 -life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

64 phy, leading to elevated N-terminal probrain natriuretic peptide (NT-proBNP) levels.

65 (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT

66 c troponin T (hs-cTnT) and N-terminal B-type natriuretic peptide (NT-proBNP) were measured using seru

67 troponin I (hs-cTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-

68 eactive protein (CRP), N-terminal pro b-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTn

69 ary biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP), urine output (UOP), and

70 e assessments included N-terminal pro-B-type natriuretic peptide (NT-proBNP).

71 y score (KCCQ-OSS) and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

72 p = 0.003), and higher N-terminal pro-B-type natriuretic peptide (p = 0.02) than those with <=Mild TR

73 e (p < 0.0001) or clinical score plus B-type natriuretic peptide (p = 0.02).

74 exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all).

75 ; Meng test p = 0.03), N-terminal pro-B-type natriuretic peptide (r = 0.56 vs. r = 0.17; Meng test p

76 ed cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0.6 pg/m

77 divided into a labeled data set (with B-type natriuretic peptide [BNP] result as a marker of CHF) and

78 >=6 ng/L] and stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] >=100 pg/mL) can inform

79 tom classification, and N-terminal pro-brain natriuretic peptide [NT-proBNP] level) at 6 months, 20 e

80 nins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline sus

81 .03]), and markers of cardiac stretch (brain natriuretic peptide [P < .001] and N-terminal fragment o

82 N-terminal fragment of the prohormone brain natriuretic peptide [P = .001]) in HIV.

83 t AF-associated human variant p.Ile138Thr in natriuretic peptide A (NPPA) encoding the atrial natriur

84 Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events after nonc

85 signaling by extracellular peptides (C-type natriuretic peptide and EGF receptor ligands) maintain t

86 impairment, and higher N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T conc

87 key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin-angioten

88 size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalization or

89 biomarkers of post-MI HF: N-terminal B-type natriuretic peptide and troponin T, and newly emergent b

90 l capacity, biomarkers (N-terminal pro-brain natriuretic peptide and/or high-sensitivity troponin T),

91 cubitril/valsartan on results from different natriuretic peptide assays.

92 ent effect on N-terminal prohormone of brain natriuretic peptide at 18 months was observed in the ove

93 siran lowered N-terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ra

94 mRNA expression of myosin heavy chain 7 and natriuretic peptide B is up-regulated in both ventricles

95 (P=0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%-47%), P=0.038.

96 sus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL;

97 acellular fluid volume, and in plasma B-type natriuretic peptide concentration (ratio of intervention

98 in 6 min, and N-terminal prohormone of brain natriuretic peptide concentrations between the 2 groups.

99 ese findings are important for comparison of natriuretic peptide concentrations in heart failure and

100 Short-term mechanical circulatory support, natriuretic peptide decile, glomerular filtration rate,

101 N-terminal pro-B-type natriuretic peptide declined significantly in all 4 subg

102 rotein kinase IIdelta phosphorylation, brain natriuretic peptide expression, and sustained capillariz

103 The concept of natriuretic peptide guidance has been extensively studie

104 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquartile ran

105 d in cardiomyocytes that converts pro-atrial natriuretic peptide into atrial natriuretic peptide, a c

106 yocardial infarction, indicating that B-type natriuretic peptide is required to preserve postinfarct

107 EF was 56%; and median N-terminal pro-brain natriuretic peptide level was 1403 pg/mL; 761 (96.5%) co

108 ents were women, median N-terminal pro-brain natriuretic peptide level was 918 pg/ml (interquartile r

109 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI,

110 have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with incon

111 ile concurrently reducing circulating atrial natriuretic peptide levels (p < 0.01).

112 N-terminal pro-B-type natriuretic peptide levels decreased similarly in both g

113 roBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardl

114 N-Terminal pro-B type natriuretic peptide levels were below the level consider

115 ociation class II or III HFpEF with elevated natriuretic peptide levels were enrolled between May 10,

116 aride binding protein, troponin T, and brain natriuretic peptide levels were measured.

117 h HFrEF (ejection fraction </=40%), elevated natriuretic peptide levels within the prior 30 days, and

118 uality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis.

119 s feasibility, on-study retention, trends in natriuretic peptide levels, quality of life, and safety

120 0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels.

121 he reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertrophy.

122 ing coronary angiography, independent of the natriuretic peptide NT-proBNP, kidney function and of ma

123 or soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessment beyon

124 -type, endothelium-specific CNP(-/-), global natriuretic peptide receptor (NPR)-B(-/-) and NPR-C(-/-)

125 Human genetic variation in the NPR1 (natriuretic peptide receptor 1 gene, encoding NPR-A, atr

126 tide receptor 1 gene, encoding NPR-A, atrial natriuretic peptide receptor 1) was recently shown to af

127 Mutations in natriuretic peptide receptor 2 (Npr2) gene cause a rare

128 ferentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-co

129 e G-protein-coupled clearance receptor NPR3 (natriuretic peptide receptor 3).

130 the interaction between ANP and its receptor natriuretic peptide receptor A and reduces intracellular

131 cking gastrin-releasing peptide receptor and natriuretic peptide receptor A by genetic approaches or

132 ecifically for the interaction of human anti-natriuretic peptide receptor A IgG4 with the neonatal Fc

133 ncluding gastrin-releasing peptide receptor, natriuretic peptide receptor A, neuromedin B receptor, a

134 for IgG4 (S228P), an antibody targeting the natriuretic peptide receptor A, show a previously unreco

135 CFs via the atrial/brain natriuretic peptide-natriuretic peptide receptor-1 pathway is implicated in

136 ANP acting through natriuretic peptide receptor-A (NPRA) lowers blood press

137 nction using Npr1 (encoding guanylyl cyclase/natriuretic peptide receptor-A, GC-A/NPRA) gene-knockout

138 e learned of the potential role of an NPR-C (natriuretic peptide receptor-C) in atrial fibrosis and t

139 ough specific NP receptors, including NPR-C (natriuretic peptide receptor-C), are cardioprotective ho

140 in myocytes, as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-2808 sign

141 as endothelin-1 caused itch-selective B-type natriuretic peptide release.

142 Important clinical entities associated with natriuretic peptide research include heart failure, obes

143 betes, renal function, N-terminal pro-b-type natriuretic peptide serum concentration, and right ventr

144 hy (MRN) with hsTNT and N-terminal pro-brain natriuretic peptide serum levels in patients with T2D.

145 G1 is a primary effector of nitric oxide and natriuretic peptide signalling, and protects against hea

146 of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for risk stra

147 Atrial natriuretic peptide together with PDE9a inhibitor were a

148 In primary human keratinocytes, B-type natriuretic peptide upregulated genes promoting dermatol

149 s were normal, whereas N-terminal pro B-type natriuretic peptide was 10 times the upper limit of norm

150 core >2, or NT-proBNP (N-terminal pro-B-type natriuretic peptide) >=40 pmol/L and among participants

151 <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH

152 -197) ng/L, NT-proBNP (N-terminal-pro-B-type natriuretic peptide) 624 (307-1312) ng/L, hs-cTnI (high

153 NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 identifie

154 re (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with

155 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide

156 of cardiac biomarkers (troponins and B-type natriuretic peptide) and cardiac dysfunction for 24-48 h

157 contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity tropon

158 NT-proBNP (N-terminal pro-brain-type natriuretic peptide) and myocardial perfusion reserve we

159 Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro B-typ

160 natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardiography

161 eptide) and NT-proBNP (N-terminal pro B-type natriuretic peptide) are widely used to aid diagnosis, a

162 igated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI.

163 (28-scanning point method), and BNP (B-type natriuretic peptide) assessment during supine exercise e

164 e levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) by 36% (32 800 +/- 24 300 ng/L to 2

165 Assessment of BNP (B-type natriuretic peptide) has also been suggested by the Amer

166 Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 millio

167 Background NT-proBNP (N-terminal pro-B-type natriuretic peptide) is useful in diagnosis and prognost

168 NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multipar

169 ukin-6) and NT-proBNP (N terminal pro B-type natriuretic peptide) levels were examined in multivariab

170 n fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index, brach

171 ncluding 4-dimensional flow, BNP (brain-type natriuretic peptide) measurement, functional capacity as

172 T (cTnT) and N-terminal prohormone of brain natriuretic peptide) related to hemodynamic activity.

173 g levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF.

174 quartile range) concentration of BNP (B-type natriuretic peptide) was 124 (69-197) ng/L, NT-proBNP (N

175 Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL).

176 NT-proBNP (N-terminal pro-B-type natriuretic peptide) was not affected.

177 levation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible.

178 RI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (chi(2), 62.2; P<0.00

179 onal area, and the expression of ANP (atrial natriuretic peptide) were significantly attenuated in th

180 atrial natriuretic peptide), BNP (brain-type natriuretic peptide), and cGMP, and decreased plasma end

181 ial volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and fibrosis biomarkers; and lower

182 onin T (hsTnT), NT-proBNP (N-terminal B-type natriuretic peptide), and growth differentiation factor-

183 ckness, increased lung levels of ANP (atrial natriuretic peptide), BNP (brain-type natriuretic peptid

184 changes in NT-proBNP (N-terminal pro-B-type natriuretic peptide), cardiac reverse remodeling, and he

185 ss and log-transformed N-terminal brain-type natriuretic peptide), cTSD was predictive of preclinical

186 (atrial natriuretic peptide) and BNP (B-type natriuretic peptide), encoded by the clustered genes Npp

187 e protein), NT-proBNP (N-terminal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin), and s

188 lso assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive protein),

189 cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic peptide), interleukin (IL)-6, and E-selectin

190 troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-reactive pro

191 ips between NT-proBNP (N-terminal Pro-B-type natriuretic peptide), systolic blood pressure, and diast

192 circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-alpha, IL-6, IL-12, IL-17, mal

193 levation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), were eligible.

194 he NT-proBNP (N-terminal prohormone of brain natriuretic peptide)-a biomarker that is used for screen

195 in T) and dysfunction (N-terminal pro-B-type natriuretic peptide).

196 ate) on binding of ANP, BNP (atrial or brain natriuretic peptide).

197 tocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).

198 of-life, and NT-proBNP (N-terminal pro-brain natriuretic peptide).

199 biomarkers (including N-terminal pro-B-type natriuretic peptide).

200 s pro-atrial natriuretic peptide into atrial natriuretic peptide, a cardiac hormone that regulates bl

201 Npr2 abolished protective effects of C-type natriuretic peptide, a ligand for Npr2, against death of

202 Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral

203 Plasma aldosterone, B-type natriuretic peptide, active renin concentration, and cli

204 lar markers, including Nppb, encoding B-type natriuretic peptide, after infarction.

205 dinal strain, N-terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compar

206 ve Risk Evaluation II, N-terminal pro-B-type natriuretic peptide, and cardiac troponin T concentratio

207 sma norepinephrine and N-terminal pro-B-type natriuretic peptide, and chemosensitivity to hypercapnia

208 , randomized treatment, N-terminal pro-brain natriuretic peptide, and clinical risk factors.

209 y greater reduction in N-terminal pro-B-type natriuretic peptide, and improved clinical outcomes comp

210 iltration rate, higher N-terminal pro-B-type natriuretic peptide, and lower peak Vo(2).

211 rular filtration rate, N-terminal pro-B-type natriuretic peptide, and peak oxygen consumption (Vo(2))

212 otein, lipoprotein(a), N-terminal pro-B-type natriuretic peptide, and transferrin), and apolipoprotei

213 reatine kinase, myoglobin, N-terminal B-type natriuretic peptide, C-reactive protein, and leukocyte c

214 of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large ani

215 inical information (eg, N terminal pro-brain natriuretic peptide, distinctive chest x-ray findings, a

216 er adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and left v

217 baseline to week 12 in N-terminal pro-B-type natriuretic peptide, ejection fraction, global longitudi

218 antly raised levels of N-terminal pro B-type natriuretic peptide, ferritin, D-dimers, and cardiac tro

219 Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment, and m

220 ensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation factor-15, a

221 on, Galectin-3 (Gal-3), N-terminal proB-type natriuretic peptide, high sensitivity troponin T (hsTnT)

222 ronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T

223 ion in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common

224 rritin, procalcitonin, N-terminal pro B-type natriuretic peptide, interleukin-6 level, and D-dimers.

225 augmentation index at 12 months, BP, B-type natriuretic peptide, or physical function.

226 l cyclase activity, increased sensitivity to natriuretic peptide, or reduced the Michaelis constant i

227 ft ventricular ejection fraction, pro-B-type natriuretic peptide, troponin I, and C-reactive protein

228 cardiomyocytes and CFs via the atrial/brain natriuretic peptide-natriuretic peptide receptor-1 pathw

229 ith the cardiac marker N-terminal pro-B-type natriuretic peptide.

230 -dependent degradation of vasodilator atrial natriuretic peptide.

231 l strain, and N-terminal prohormone of brain natriuretic peptide.

232 grades vasoactive peptides, including atrial natriuretic peptide.

233 ic variables including N-terminal pro-B-type natriuretic peptide.

234 ype natriuretic peptide (BNP) and the C-type natriuretic peptide.

235 ejection fraction and N-terminal pro-B-type natriuretic peptide.

236 itional markers, such as N-terminal probrain natriuretic peptide.

237 x turnover), ST-2, and N-terminal pro-B-type natriuretic peptide.

238 ardiac troponin T, and N-terminal pro-B-type natriuretic peptide.

239 ocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; all P<0.001).

240 -1.39]) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; hazard ratio, 1.73 [95% CI, 1.52-1.

241 decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide; P=0.002), and lower levels of PRA (

242 ponin-T and NT-proBNP [N-terminal Pro-B-type natriuretic peptide]) at baseline (pre-ERT) and 12 month

243 d change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase

244 (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).

245 , medical therapy escalation, and BNP [brain natriuretic peptide]).

246 F proteins (NT-proBNP [N-terminal pro-B type natriuretic peptide], ESM [endothelial cell-specific mol

247 higher risk: NT-proBNP [N-terminal proB-type natriuretic peptide], TSP2 [thrombospondin-2], MBL [mann

248 oming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting Na-H exchangers and s

249 Current guidelines recommend use of natriuretic peptides (N-terminal pro-B type natriuretic

250 thway, the evaluation of nitrates, synthetic natriuretic peptides (NP), and NP analogs has yielded mi

251 Natriuretic peptides (NPs) are hormones involved in main

252 Cardiac natriuretic peptides (NPs) play a fundamental role in ma

253 The cardiac natriuretic peptides (NPs), atrial NP and B-type NP, reg

254 questioned, and use of N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferred and

255 lated manner, two polypeptide hormones - the natriuretic peptides - referred to as atrial natriuretic

256 Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thr

257 the prognostic value of sST2 is additive to natriuretic peptides and (in the case of chronic HF) to

258 Some ubiquitous biomarkers, for example, natriuretic peptides and cardiac troponin, may assist in

259 e regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-a

260 Natriuretic peptides are substrates of neprilysin; hence

261 ies study heart failure risk score excluding natriuretic peptides as the base model to which we added

262 ng, a 6-minute walk test, and measurement of natriuretic peptides before and 1 year after AVR.

263 Plasma concentrations of natriuretic peptides decline with obesity in patients wi

264 Natriuretic peptides decrease RV afterload by promoting

265 with reduced ejection fraction and elevated natriuretic peptides enrolled in the COSMIC-HF trial (Ch

266 Measures of serum cardiac troponins and natriuretic peptides have become established as prognost

267 BACKGROUND AND Natriuretic peptides have led the way as a diagnostic an

268 Natriuretic peptides have many physiological actions and

269 Plasma levels of natriuretic peptides have proven to be powerful diagnost

270 linical model improved modestly after adding natriuretic peptides in men (DeltaC-statistic = 0.006; l

271 of pharmacological agents that are based on natriuretic peptides is an area of active research, with

272 Elevated natriuretic peptides occurring mid-first cycle of treatm

273 ic HF, ejection fraction >=45%, and elevated natriuretic peptides or a prior HF hospitalization.

274 Studies have reported that natriuretic peptides provide prognostic information for

275 Natriuretic peptides regulate multiple physiologic syste

276 scovery of atrial secretory granules and the natriuretic peptides stored in them identified the atriu

277 yclase receptors that mediate the effects of natriuretic peptides through the generation of intracell

278 Natriuretic peptides were highly predictive of CVAEs; ho

279 tients who fulfilled entry criteria for both natriuretic peptides were included in the present analys

280 assessed the association of levels of these natriuretic peptides with the subsequent risk of cardiov

281 NPs (natriuretic peptides) are cardiac-derived hormones that

282 NPs (natriuretic peptides), which elicit their effects throug

283 ndent prognostic value even beyond symptoms, natriuretic peptides, and Meta-Analysis Global Group in

284 Biomarker measurements included natriuretic peptides, cardiac troponins, plasminogen act

285 the relationship between cardiac troponins, natriuretic peptides, ECV and their associations with in

286 without hospitalization), and with elevated natriuretic peptides, enrolled at 167 sites in 21 countr

287 iography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficien

288 n- beyond traditional risk factors including natriuretic peptides, risk scores, and symptoms-in heart

289 These include natriuretic peptides, soluble suppressor of tumorgenicit

290 dyspnea, increased plasma concentrations of natriuretic peptides, systolic blood pressure of at leas

291 After adjusting for baseline natriuretic peptides, time-updated Meta-Analysis Global

292 tion rate >=30 mL/min/1.73m(2), and elevated natriuretic peptides.

293 riable changes in concentrations of multiple natriuretic peptides.

294 systolic function and remodeling and reduces natriuretic peptides.

295 improvements in HF-related health status or natriuretic peptides.

296 icular ejection fraction <=40%, and elevated natriuretic peptides: BNP >=150 pg/mL or NT-proBNP >=600

297 1 receptor, 5-hydroxytryptamine receptor 1F, natriuretic precursor peptide B, and neuromedin B.

298 Natriuretic regulation of extracellular fluid volume hom

299 ng nexin 1 (SNX1) in mice results in blunted natriuretic response and hypertension due to impaired do

300 Insulin therapy rescued the natriuretic response in diabetic rats, restoring normal